Period | Inclusion | Treatment | Follow-up | ||
---|---|---|---|---|---|
Baseline | First assessment | Second assessment | Third assessment | Fourth assessment | |
0 week | 2 weeks after inclusion | 4 weeks after inclusion | 8 weeks after inclusion | 12 weeks after inclusion | |
 Inclusion confirmed | √ |  |  |  |  |
 Informed consent | √ |  |  |  |  |
 Randomization and blinding | √ |  |  |  |  |
 Sociodemographic characteristics | √ |  |  |  |  |
 Disease history | √ |  | √ |  |  |
 Treatment history | √ |  | √ |  |  |
 Comorbidity | √ |  | √ | √ | √ |
 Current treatment | √ |  | √ | √ | √ |
Outcomes | |||||
 WOMAC | √ | √ | √ | √ | √ |
 VAS | √ | √ | √ | √ | √ |
 PGA |  | √ | √ | √ | √ |
Trial evaluation | |||||
 Outcome analysis |  |  |  |  | √ |
 Adverse event |  |  | √ |  |  |
 Causes of dropout |  |  | √ |  |  |
 Safety analysis |  |  | √ |  |  |
 Compliance analysis |  |  | √ |  |  |